• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Johnson & Johnson seeks new trials after $1B Pinnacle hip implant loss

Johnson & Johnson seeks new trials after $1B Pinnacle hip implant loss

February 3, 2017 By Brad Perriello

DePuy OrthopaedicsJohnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics wants a federal judge to grant new trials after it lost a $1 billion judgment to 6 plaintiffs who sued over its metal-on-metal Pinnacle hip implant.

A Dallas jury in December found that the metal-on-metal pinnacle hip implants were designed defectively and that the companies failed to appropriately warn patients of the risks associated with the devices, awarding $32 million in compensatory damages and more than $1 billion in punitive damages to the 6 co-plaintiffs. But Judge Ed Kinkeade of the U.S. District Court for Northern Texas, as he did with a similar, $500 million verdict in a previous Pinnacle lawsuit, again slashed the verdict nearly in half. The plaintiffs have appealed that ruling, according to court documents.

Now DePuy wants Kinkeade to grant new, separate trials. Barring that outcome, the company also filed 7 motions for judgment as a matter of law seeking to overturn the verdict.

“Following a trial that was rife with inflammatory and inadmissible evidence concerning matters that were wholly irrelevant to the core liability issues in the 6 plaintiffs’ cases, the jury found for each plaintiff and returned an astronomical verdict of $1.04 billion dollars. Both the damages and liability components of this verdict were the product of unfairly prejudicial evidence that should have been excluded from trial under even the most permissive interpretations of the Federal Rules of Evidence. As set forth below, if the court does not grant defendants’ [judgment as a matter of law] motions, it should strike the damages as excessive and order new trials on all issues for several reasons,” the company argued, according to the documents.

Citing “the severe prejudice and confusion that resulted from the consolidation of 6 disparate product-liability cases,” DePuy argued that lumping the cases together only confused the jury.

“Defendants repeatedly objected prior to trial that burdening the jury with the task of differentiating the individualized and complex issues arising from the claims of 6 different plaintiffs would result in significant juror confusion and severely prejudice defendants. That is precisely how these cases played out,” the company argued.

DePuy also claimed that it’s entitled to new trials “because plaintiffs injected an enormous amount of unfairly prejudicial evidence into this trial – all of which should have been excluded under any fair reading of the Federal Rules of Evidence and which led the jury to decide the case based on emotion and prejudice rather than reason.”

New trials are also in order because the compensatory and punitive damages awards are “undeniably excessive,” DePuy argued.

“While the court reduced the punitive damages award from the jury’s initial verdict of $1.009 billion to $510,509,667 for the 6 primary plaintiffs, the reduced amount – which is 18 times higher than the inflated award of compensatory damages – still falls far outside the ‘single-digit ratio’ representing the ‘outermost limit of the due process guarantee [emphasis theirs],'” the company wrote.

The lawsuits are the 3rd clutch of bellwether cases to go to trial of the nearly 9,000 in a multi-district litigation overseen by Kinkeade. DePuy won the 1st bellwether trial in the MDL, in October 2014. In July Kinkeade slashed the $500 million judgment in the 2nd bellwether proceeding to roughly $151 million.

Filed Under: Implants, Legal News, Metal-on-Metal Tagged With: depuysynthes, Johnson and Johnson

In case you missed it

  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says
  • ControlRad gains clearance for imaging tech to sell to Boston Sci
  • Capsule lands Frost & Sullivan award for remote ventilator monitor
  • Philips debuts AI-enhanced imaging platform
  • Pulmatrix completes $40M offering, updates product pipeline timetable
  • Medtronic launches IDE trial for AFib tech
  • Medtronic hiring Walmart exec to run its supply chain
  • An Overview of IEC 60601-1 3rd Edition, 2nd Amendment
  • Report: Permira eyeing LivaNova purchase
  • Amgen to acquire Five Prime Therapeutics for $1.9B
  • Medtronic wins city council approval for 42-acre campus in Colorado
  • Conformis dips 9% on Street-beating Q4 results
  • Becton Dickinson acquires smart medication device maker GSL Solutions
  • FDA clears once-daily ADHD capsule from Corium
  • Philips and Disney want to make MRIs easier for children: Here’s how
  • Origami Surgical gains FDA clearance for robotic suturing devices

RSS From Medical Design & Outsourcing

  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS